Compugen (CGEN) Stock Price, News & Analysis

Company Overview

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression. By integrating genomic, transcriptomic and proteomic data, the platform accelerates target identification and reduces the timelines typically associated with early-stage drug discovery. The company applies this technology both to its internally developed pipeline and to partnered research programs.

The company’s pipeline includes multiple clinical-stage immuno-oncology candidates, among them checkpoint modulators advancing in Phase 1 trials for solid tumors. In parallel, Compugen is developing companion diagnostic and biomarker assays designed to predict patient response and optimize therapeutic regimens. Strategic collaborations with global pharmaceutical partners have enabled the advancement of select programs into later-stage development and expanded the geographic reach of its assets.

Over its three-decade history, Compugen has built a multidisciplinary team of computational biologists, immunologists and clinical development experts. This leadership group oversees both discovery and translational research efforts, with the goal of delivering novel immunotherapy solutions across North America, Europe and Asia. Through its integrated approach, Compugen aims to bring first-in-class therapies and precision diagnostic tools to patients with unmet medical needs.

Key Stats

• Today's Range: $1.96 to $2.08
• 50-Day Range: $1.96 to $3.10
• 52-Week Range: $1.30 to $3.24
• Volume: 503,830 shs
• Average Volume: 451,018 shs
• Market Capitalization: $190.05 million
• P/E Ratio: 5.43
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Compugen Stock Analysis - MarketRank™

Compugen scored higher than 76% of companies evaluated by MarketBeat, and ranked 151st out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Compugen has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Compugen has a consensus price target of $5.00, representing about 148.8% upside from its current price of $2.01.

Amount of Analyst Coverage

Compugen has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Compugen are expected to grow in the coming year, from ($0.28) to ($0.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compugen is 5.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compugen is 5.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.56.

Price to Book Value per Share Ratio

Compugen has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.86% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 3.93, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Compugen has recently increased by 44.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compugen does not currently pay a dividend.

Dividend Growth

Compugen does not have a long track record of dividend growth.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.05

News Sentiment

Compugen has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Compugen this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Compugen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,789.00 in company stock.

Percentage Held by Insiders

9.50% of the stock of Compugen is held by insiders.

Percentage Held by Institutions

12.22% of the stock of Compugen is held by institutions.

Company Calendar

• Last Earnings: 5/18/2026
• Today: 6/20/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGEN
• CIK: 1119774
• Web: www.cgen.com
• Phone: (723) 765-8585
• Fax: 972-3765-8555
• Employees: 70
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Compugen: $5.00
• High Price Target: $6.00
• Low Price Target: $4.00
• Potential Upside/Downside: +148.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.37
• Trailing P/E Ratio: 5.43
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $35.34 million
• Net Margins: 47.97%
• Pretax Margin: 48.01%
• Return on Equity: 47.72%
• Return on Assets: 27.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.23
• Quick Ratio: 6.23

Sales & Book Value

• Annual Sales: $72.76 million
• Price / Sales: 2.61
• Cash Flow: $0.37 per share
• Price / Cash Flow: 5.38
• Book Value: $1.09 per share
• Price / Book: 1.84

Miscellaneous

• Outstanding Shares: 94,550,000
• Free Float: 85,570,000
• Market Cap: $190.05 million
• Optionable: Optionable
• Beta: 2.74